The Valley Desk

NCT03051256 · Interventional trial

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Overall registry status Completed

Phase 2

Conditions Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov